Sensus Healthcare (NASDAQ:SRTS) Price Target Cut to $10.00 by Analysts at Maxim Group

Sensus Healthcare (NASDAQ:SRTS) had its price target decreased by Maxim Group from $14.00 to $10.00 in a report issued on Monday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Several other equities analysts have also commented on SRTS. Lake Street Capital dropped their target price on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Sensus Healthcare in a report on Friday, April 4th.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $4.73 on Monday. The firm has a market cap of $78.02 million, a PE ratio of 11.83 and a beta of 1.30. The firm has a 50 day simple moving average of $4.61 and a 200-day simple moving average of $6.10. Sensus Healthcare has a 1-year low of $4.01 and a 1-year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. The business had revenue of $8.34 million during the quarter, compared to analyst estimates of $7.23 million. As a group, sell-side analysts expect that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensus Healthcare

A number of large investors have recently modified their holdings of SRTS. American Century Companies Inc. raised its holdings in shares of Sensus Healthcare by 12.7% during the 1st quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock valued at $106,000 after buying an additional 2,520 shares during the period. JPMorgan Chase & Co. acquired a new stake in Sensus Healthcare in the fourth quarter valued at approximately $27,000. Sachetta LLC raised its stake in shares of Sensus Healthcare by 4.1% during the first quarter. Sachetta LLC now owns 124,887 shares of the company’s stock valued at $591,000 after purchasing an additional 4,945 shares during the period. Chapin Davis Inc. lifted its position in shares of Sensus Healthcare by 50.0% during the first quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $71,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Barclays PLC purchased a new position in shares of Sensus Healthcare in the fourth quarter valued at $35,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.